| |
Total
|
Male
|
Female
|
|---|
|
β
|
95%-CI
|
p-value
|
β
|
95%-CI
|
p-value
|
β
|
95%-CI
|
p-value
|
|---|
|
FEV1a
|
|
SHS exposureb
|
−44
|
(−82, −5)
|
0.03
|
−75
|
(− 140, − 11)
|
0.02
|
−13
|
(− 57, 31)
|
0.56
|
|
SHS exposure*follow-up timec
|
1
|
(0, 3)
|
0.03
|
2
|
(0, 4)
|
0.03
|
1
|
(−1, 3)
|
0.19
|
|
FVCa
|
|
SHS exposureb
|
− 56
|
(−102, − 10)
|
0.02
|
− 102
|
(− 179, − 24)
|
0.01
|
−19
|
(−71, 33)
|
0.47
|
|
SHS exposure*follow-up timec
|
2
|
(0, 4)
|
0.02
|
3
|
(0, 6)
|
0.03
|
2
|
(0, 4)
|
0.09
|
|
FEV1/FVCa
|
|
SHS exposureb
|
0.0
|
(− 0.5, 0.5)
|
0.96
|
0.1
|
(− 0.6, 0.9)
|
0.71
|
0.1
|
(−0.6, 0.7)
|
0.88
|
|
SHS exposure*follow-up timec
|
0.0
|
(0.0, 0.0)
|
0.94
|
0.0
|
(0.0, 0.0)
|
0.96
|
0.0
|
(0.0, 0.0)
|
0.62
|
- Models are adjusted for age, age squared, weight, weight squared, height, combination of smoking status and pack years, maternal smoking, paternal smoking, allergic sensitisation, education and exposure to dust/fumes as well as for sex in the total study population
- aan interaction term between time between follow-ups and SHS exposure is included to determine the effect of SHS exposure on lung function decline
- ba negative estimate suggests that those exposed to SHS at the first examination had lower average lung function at all three examinations than those not exposed
- ca negative estimate suggests that those exposed to SHS at the first examination had a higher decline in lung function between the examinations than those not exposed
- * indicating the interaction term between SHS exposure and time of follow-up
